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Study design: We report on the long-term outcome and effects of bosentan treatment in
Taiwanese patients with advanced (functional class III or IV) idiopathic pulmonary arterial
hypertension (IPAH).
Materials and methods: IPAH patients on stable bosentan therapy for more than
12 months and regularly monitored were eligible for this prospective uncontrolled study.
Patients were evaluated for several clinical parameters, both measured at the time of
initiation of bosentan therapy and after 12 months on therapy: New York Heart Association
functional class (NYHA FC), change in 6-min walk distance (6MWD), right ventricle ejection
fraction (RVEF), cardiothoracic ratio (CTR), and pulmonary functional status.
Results: Twelve of 15 patients met eligibility requirements and were enrolled. Their mean
age was 37.6712.9 years and 92% were female. Six (50%) patients were in NYHA FC IV and
the others were in NYHA FC III at baseline. Three (25%) patients were chronic hepatitis C
virus (HCV) carriers, with normal liver function. After 12 months of bosentan treatment,Elsevier Ltd. All rights reserved.
ansferase; AST, aspartate aminotransferase; ET, endothelin; MPAP, mean pulmonary artery pressure;
pertension; ULN, upper limit of normal; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; AFP,
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Oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension 15576-MWD, RVEF, and pulmonary function all increased signiﬁcantly. CTR and NYHA FC both
decreased signiﬁcantly. Oral bosentan was well tolerated and there was no episode of liver
dysfunction that required adjustment of the bosentan dosage or discontinuance of therapy.
Conclusion: Long-term treatment with oral bosentan appears to have beneﬁcial effects on
functional status, exercise capacity, right heart function, and pulmonary function in
Taiwanese patients with advanced IPAH, regardless of whether or not they presented with
chronic HCV infection.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary arterial hypertension (IPAH), formerly
named primary pulmonary hypertension, is an uncommon
disorder of unknown aetiology. The major characteristics are
progressive increase in pulmonary artery pressure (PAP) and
pulmonary vascular resistance, which often lead to right heart
failure and death, especially in patients in New York Heart
Association functional class (NYHA FC) III or IV.1 In the national
North American Registry of 194 patients with IPAH, the median
survival was only 2.8 years without speciﬁc treatment.2
The treatment of IPAH has realized dramatic advances
over the past decade. Bosentan (Tracleer, Actelion Pharma-
ceuticals, Allschwil, Switzerland), a non-peptide antagonist
blocking both endothelin A and B receptors, is the ﬁrst oral
therapy approved for the treatment of pulmonary arterial
hypertension (PAH) in North America and Europe. Recently,
there were a number of clinical studies showing that
bosentan therapy improved not only functional class and
exercise performance, but also quality of life in sympto-
matic patients with PAH.3–5 Therefore, for many clinicians,
bosentan provided an appealing alternative to epoprostenol
as ﬁrst line treatment in patients with severe symptomatic
IPAH; however, much of this clinical research focused on the
white population. Although Sasayama et al. demonstrated
that 12 weeks of bosentan treatment resulted in improve-
ment in symptoms, hemodynamics, and quality of life in 18
patients with PAH recruited from 11 Japan centres,6 the
long-term outcome and beneﬁts of bosentan therapy among
the Asian populations are still largely unknown.
In Taiwan, recent history shows that clinicians relied on the
use of prostanoids (intravenous epoprostenol or inhaled
iloprost) for medical treatment of advanced IPAH.7 Since
October 2003, oral bosentan was approved by health
administrative ofﬁcial in Taiwan to treat advanced IPAH
patients. Given the ease of administration and well-docu-
mented clinical beneﬁts of bosentan, ﬁrst-line treatment
with bosentan for advanced IPAH patients is considered both
reasonable and feasible. We describe the long-term outcome
and effects of bosentan treatment on functional class,
exercise capacity, clinical response, and adverse events in
Taiwanese patients with severe symptomatic IPAH.Methods
Patient selection
From October 2003 to February 2005, 15 consecutive
patients with advanced IPAH whose age was greater than12 years and received bosentan as the ﬁrst-line therapy in
our institute were enrolled. All patients were classiﬁed as
being in NYHA FC III or IV, despite optimal medical therapy,
including the use of anticoagulants, diuretics, cardiac
glycosides, vasodilators and supplemental oxygen. The
diagnosis of IPAH was rendered by standard diagnostic
criteria established at the third World Conference on
Pulmonary Hypertension, held in Venice in 2003.7 Exclusion
criteria were non-IPAH, a positive response to acute
vasodilator challenge during right heart catheterization,
impaired liver function (serum alanine aminotransferase
(ALT) or aspartate aminotransferase (AST) greater than two
times the upper limit of normal (ULN)) at baseline and
previous exposure to prostanoids (intravenous epoprostenol
or inhaled iloprost). Three patients without pre-existing
liver disease were excluded from this study in the initial
4 weeks after starting bosentan treatment. Two patients had
elevation of hepatic aminotransferases greater than ﬁve
times the ULN while on bosentan 62.5mg twice daily and the
other patient needed to combination therapy with inhaled
iloprost due to clinical worsening of PAH while on bosentan.
For patients with chronic hepatitis C virus (HCV) infection,
the expert hepatologists were routinely consulted to conﬁrm
that there was no clinical evidence or symptoms of portal
hypertension. Furthermore, serum a-fetoprotein (AFP),
hepatic ultrasound, and the quantitative HCV RNA assay
were examined at baseline and every 6 months after starting
bosentan treatment to early detect the signs of hepatocel-
lular carcinoma (HCC) development or active HCV replica-
tion. No patient was lost to follow up, and the vital statuses
of all patients were conﬁrmed in February 2006. This study
was approved by our institutional review committee and the
informed consent was obtained from all patients prior to
their enrolment.
Bosentan treatment
Patients received a starting dose of bosentan 62.5mg twice
daily and this was increased and maintained at 125mg twice
daily after 4 weeks. ALT and AST were routinely monitored
because of bosentan’s known adverse effects on hepatocel-
lular enzymes. Follow-up visits were scheduled in the
second week and fourth weeks after starting bosentan
therapy and then every 4 weeks thereafter. At each follow-
up visit, data on clinical events, functional status, and
adverse events were carefully recorded. If increases in ALT
or AST levels were to a value greater than three times ULN,
the bosentan dosage was reduced to 62.5mg twice daily. If
increases in ALT or AST levels were to a value greater than
ﬁve times the ULN, bosentan treatment was discontinued
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Baseline characteristics
The baseline evaluation included a medical history, physical
examination, routine blood tests and right heart catheter-
ization using standard techniques. The clinical effects were
determined by assessing the NYHA FC, 6-min walk distance
(6MWD), right ventricle ejection fraction (RVEF), cardi-
othoracic ratio (CTR) and pulmonary function tests. All
variables were examined prior to initiation of bosentan
therapy and for 12 months thereafter.
NYHA FC assessment
The functional class of each patient was determined using
a standardized protocol according to the Venice 2003
classiﬁcation,8 including questions concerning the patient’s
daily life.
Six-minute walk test (6MWT)
This test provides a standardized, objective, integrated
assessment of cardiopulmonary and musculoskeletal func-
tion that is relevant to daily activities. The self-paced 6MWT
assesses the sub-maximal level of functional capacity and is
widely applied as a long-term follow up effect for IPAH
treatment. All patients were told to use their own pace, but
to cover as much ground as possible in 6min. Patients who
were unable to perform the test were recorded as achieving
a distance of 0m.
Right ventricle ejection fraction
After injection with 20mCi technetium 99m (99mTc)-labelled
RBCs, radionuclide angiography using the gated blood pool
technique was performed to measure the RVEF at rest. The
results are shown as the RVEF percentage; the normal value
in our institute is greater than 40%.
Cardiothoracic ratio
Cardiothoracic ratio was determined only where a standard
posteroanteior (PA) chest ﬁlm was available. It is the
transverse cardiac diameter (the horizontal distance be-
tween the most rightward and leftward borders of the heart
seen on a PA chest radiography) divided by the transverse
chest diameter (measured from the inside rib margin at the
widest point above the costophrenic angles on the PA chest
ﬁlm).
Pulmonary functional tests
The spirometric testing (forced vital capacity, FVC; forced
expiratory volume in 1 s, FEV1) was performed according to
the standards of the American Thoracic Society.9 Lung
function reference values corrected for sex, age, and height
were used. The FVC and FEV1 results are shown as
percentages of predicted value, which were compared withthe normative data that widely used as the reference data in
our institute.
Statistical analysis
Baseline and follow-up information were summarised for the
12 patients who completed this study without missing data.
All paired changes from baseline to month 12 were
evaluated using the Wilcoxon signed-rank test. To avoid
the potential of biasing the results of this uncontrolled,
small-sample-size study, no imputation for missing values
was used. Continuous variables were summarized as
the means7SDs. All reported p values are two sided
and p values less than 0.05 were considered statistically
signiﬁcant.
Results
Baseline characteristics
From October 2003 to February 2005, 12 patients with
severe IPAH were eligible for this analysis. The baseline
demographic and haemodynamic characteristics of these
patients are shown in Table 1. Patients ranged in age from 14
to 57 years, with a mean age of 37.6712.9 years. Eleven of
the patients were female and 3 of 9 (75%) patients with
mean pulmonary artery pressure (MPAP) greater than
50mmHg. Six (50%) patients presented in NYHA FC IV and
eight (75%) patients had a history of right heart failure.
Three (25%) patients were diagnosed as HCV carriers, based
on positive test results for antibodies to HCV (by second-
generation enzyme-linked immunoassay). Two patients had
cirrhotic livers based on characteristic ultrasonographic
patterns. All three patients presented with normal liver
function, normal serum AFP levels, and undetectable
serum HCV RNA by quantitative assays before initiation of
bosentan.
Clinical parameter changes
Of the 12 patients enrolled in the trial, six (50%) were in
NYHA FC III and 6 patients (50%) were in class IV at baseline.
The NYHA functional status signiﬁcantly improved from 3.5
at baseline to 2.25 after 12 months of treatment (p ¼ 0:002)
(Table 2). At month 12, 9 patients (75%) were reclassiﬁed in
to class II and 3 patients (25%) were reclassiﬁed to class III
(Fig. 1); 4 patients improved from class IV to II, 2 patients
improved from class IV to III, 5 patients improved from class
III to II, and 1 patient remained in class III although their
6MWD lengthened by 20m. Two of the three HCV carries
improved from class IV to II, and the other improved
from class IV to III. None of the 12 patients completing
the 12-month study deteriorated or were reclassiﬁed to
class IV (Fig. 1).
For all patients, 6MWD increased from 3267138m at
baseline to 4467119m at month 12, an increase of 37%
(p ¼ 0:002) (Table 2). The RVEF percentage increased from
31.0717.1% at baseline to 54.5712.2% at month 12
(p ¼ 0:004). The CTR decreased, i.e., improved from
0.55170.066 at baseline to 0.50870.049 at month
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Table 1 Patient characteristics at baseline.
Patient no. Gender Age (yr) MPAP (mmHg) NYHA FC History of right heart failure HCV carrier Cirrhosis
1 Female 29 72 IV +
2 Female 24 49 IV + +
3 Female 40 51 III
4 Female 37 68 III +
5 Female 41 52 III
6 Female 42 51 III
7 Female 17 75 III +
8 Male 14 80 IV +
9 Female 51 65 III
10 Female 57 40 IV + + +
11 Female 33 66 IV +
12 Female 43 41 IV + + +
MPAP ¼ mean pulmonary artery pressure; NYHA FC ¼ New York Heart Association Functional Class; HCV ¼ hepatitis C virus.
Table 2 Variables before bosentan treatment and at end of observation (12 months).
Baseline End of observation p value
NYHA FC 3.570.52 2.2570.45 0.002
6-MWD (m/6min) 3267138 4467119 0.002
RVEF (%) 31.0717.1 54.5712.2 0.004
Cardio–thoracic ratio 0.55170.066 0.50870.049 0.019
FVC (% predicted) 84.2714.7 95.3716.1 0.003
FEV1 (% predicted) 77.1717.7 84.0717.0 0.019
Data are presented as the mean7SD (n ¼ 12).
NYHA FC ¼ New York Heart Association Functional Class; 6-MWD ¼ 6-min walking distance; RVEF ¼ right ventricular ejection fraction;
FVC ¼ forced vital capacity; FEV1 ¼ forced expiratory volume in 1 s.
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Figure 1 Effects of oral bosentan on NYHA functional class
(n ¼ 12): change in number of patients from baseline to month
12. Except for one patient in class III at baseline who remained
class III at month 12, the others11 had at least one class
improvement. Two of the three HCV carriers improved from
class IV to II, and the other improved from class IV to III. No
patient deteriorated or was reclassiﬁed to class IV.
Oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension 155912 (p ¼ 0:019). The percentages of predicted values of FVC
and FEV1 improved from 84.2714.7% and 77.1717.7% at
baseline to 95.3716.1% (p ¼ 0:003) and 84.0717.0%
(p ¼ 0:019) at month 12, respectively.Withdraw and adverse events
Three of our original 15 patients were excluded from this
study in the initial 4 weeks due to serious adverse events
(Table 3). Two patients were excluded due to asymptomatic
increases in hepatic aminotransferase levels 5 times the ULN
on bosentan dosage 62.5mg twice daily. These increases
returned to normal after discontinuing bosentan and both
patients were switched to prostanoid therapy. The other one
patient needed combination therapy with prostanoid treat-
ment due to clinical worsening of PAH. Thus, although 15
patients were enrolled and 12-month data were only
available for 12 patients, the 3 patients not completing
the 12-month evaluation were included in the adverse
events assessments (Table 3). Except for the serious adverse
events, the most frequent adverse events were headache
and ﬂushing, both of which were reported in 20% of patients.
Additional adverse events included leg oedema, pain in the
limbs, arthralgia, and cough. For 3 IPAH patients with
chronic HCV infection, there was no episode of abnormal
hepatic function that necessitated the adjusted of bosentan
dosage or discontinuance of the treatment during the 12
months of bosentan treatment. In addition, no clinical sign
of HCC development was detectable and the serum HCV RNA
levels were persistently undetectable during and after the
12 months of bosentan treatment. Overall, bosentan
treatment was well tolerated in the 12 IPAH patients,
regardless of whether or not they were chronic HCV carriers.
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Table 3 Adverse events (n ¼ 15).
Variables n (%)
Serious adverse events
Abnormal hepatic function 2 (13)
Aggravated pulmonary hypertension 1 (7)
Adverse events
Headache 3 (20)
Flushing 3 (20)
Leg oedema 2 (13)
Pain in limb 2 (13)
Arthralgia 2 (13)
Cough 1 (7)
H.-H. Hsu et al.1560Discussion
The present study reports the ﬁrst trial investigating the
long-term outcome and effects of bosentan in the treatment
of advanced IPAH among Asian patients. In this study,
bosentan demonstrated favourable exercise effects, includ-
ing improved NYHA functional status and 6MWD after 12
months of treatment. These effects were accompanied
by an increase in RVEF, improvements in FVC and FEV1
and a reduction in CTR. Except for the 3 patients who
withdrew in the initial 4 weeks, the long-term effects of
bosentan was further supported by the fact that none
of the 12 patients with advanced IPAH monitored for more
than 1 year presented with clinical worsening of PAH during
this study. Furthermore, after 12 months of treatment,
there was no episode of apparently abnormal hepatic
function, no evidence of active HCV replication, and no
sign of HCC development in the 3 patients with chronic HCV
infection.
Meyer et al.10 reported that FVC and FEV1 were
signiﬁcantly reduced among the 171 IPAH patients they
characterized, compared to the predicted values of 64
non-smoking control volunteers without pulmonary or
cardiac dysfunction. They reported that peripheral airway
obstruction was common in IPAH and was more pronounced
in severe disease. One of the reasons for poor pulmonary
test results is that the increased production of cytokines and
growth mediators in the pulmonary vasculature in IPAH
might cause proliferation in adjacent small airways.11
Another reason is that decreased endothelial synthesis of
the vasodilator nitric oxide and increased levels of the
vasoconstrictor endothelin-1 (ET-1) in IPAH patients
might also affect peripheral airway function since both
mediators have similar effects on vascular and airway
smooth musculature.12–14 However, it remained to be
determined whether an increase in an ET-1 receptor
antagonist, such as bosentan, could improve the function
of peripheral airways in IPAH patients. In this study, we
demonstrated that FVC and FEV1 both signiﬁcantly improved
after 12 months of bosentan treatment in patients with
severe IPAH. Since expiratory airﬂow limitation may
contribute to symptoms and exercise limitation in patients
with advanced IPAH, long-term bosentan treatment could
pharmacologically reverse the phenomenon of peripheralairway obstruction. This ﬁnding implies that the functional
limitations of patients with IPAH are not only caused by
progressive right heart failure and impaired pulmonary gas
exchange, but also by peripheral airway obstruction, which
can be pharmacologically reversed by long-term bosentan
treatment.
There are few well-documented non-invasive parameters
to predict right heart function and efﬁcacy of bosentan
treatment in IPAH patients. Radionuclide angiographic
measurement of ejection fraction is a widely used
method for the non-invasive assessment of ventricular
function. Gated imaging of the equilibrium blood pool was
the ﬁrst reliable and reproducible radionuclide technique
proposed for the measurement of RVEF.15–18 Furthermore,
the size of the heart, as assessed by CTR on chest
radiography is often used as a screening test for the
presence of heart failure and for assessing its severity.19,20
In our study, the signiﬁcant improvements in RVEF and
reduction in CTR after 12 months of bosentan therapy
implied improvement in right heart function and the
effectiveness of bosentan treatment in IPAH. Long-term
observation and survival analysis in a large number of IPAH
patients are needed to determine whether or not these
factors could be of non-invasive prognostic value in IPAH
treatment.
Both the NYHA FC and 6MWD are independent predictors
of mortality in IPAH.21,22 After 12 months of bosentan
therapy, the NYHA FC improved signiﬁcantly in almost all
patients. Eleven of the 12 patients had at least a one class
improvement in NYHA FC, and no patient worsened. The
difference in 6MWD between baseline and the 12-month
follow-up was 120m and the increase in length was high
relative to that of other clinical trials. One potential
explanation for the relative improvement is that sicker
patients may have a tendency to improve more with regard
to 6MWD than less severely ill patients.23 In this study, 6 of
the 12 patients were classiﬁed in NYHA FC IV at baseline and,
furthermore, the mean baseline walk distance of 326m in
the 12 patients was even lower than in the pivotal trial by
Sitbon and colleagues (351m for the bosentan group).24 The
other explanation is that all the changes in clinical
parameters after 12 months of therapy contributed to the
ﬁnal clinical status in the patients receiving bosentan. The
signiﬁcant improvements in the RVEF and pulmonary
function, and the reduction in CTR contributed to enhance
the exercise tolerance. Our results imply that the signiﬁcant
improvements in exercise capacity, RVEF, pulmonary func-
tion and reduced CTR correlated well with the clinical
response in these patients and reinforced the efﬁcacy of oral
bosentan therapy. Because the small size of our study
precludes generalisation to larger IPAH patient populations,
larger studies will be required in order to conﬁrm our
results.
Because of interaction with bile-salt excretion from
hepatocytes, liver toxicity is a typical side effect, which
occurs in approximately 5–10% of patients.3,4 In this study, 2
(13%) of our initial 15 patients were excluded from the study
due to asymptomatic elevated liver function tests in the ﬁrst
4 weeks of bosentan therapy. However, these increases
quickly returned to normal after discontinuing bosentan,
without any consequent complication. After a mean treat-
ment period of 19.475 months, 12 (80%) of the original
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complications of hepatic dysfunction requiring dosage
adjustment or discontinuance.
Chronic HCV infection, although generally indolent, could
lead to liver cirrhosis or HCC.25–27 There are serious safety
concerns regarding the administration of bosentan in IPAH
patients with pre-existing hepatic disease since potential
hepatotoxicity is a well-recognised side-effect of bosentan.
Hoeper et al. reported that bosentan was efﬁcacious
and safe in their eleven patients with portopulmonary
hypertension; however, the majority of their aetiology was
alcoholic liver disease.28 In this study, 3 IPAH patients
diagnosed as HCV carriers without symptoms of portal
hypertension tolerated bosentan therapy well for more than
12 months. At month 12, two patients’ symptoms had
improved such that they were reclassiﬁed into NYHA FC II,
while the other was reclassiﬁed into NYHA FC III. Most
notably, there was no evidence for drug-induced liver
toxicity that required bosentan dosage adjustment or any
episode of severe adverse event leading to withdrawal
from this study. Hepatic aminotransferase levels were
normal or slightly abnormal (less than 3 times the ULN).
The quantitative assays of HCV RNA, which indicate the
status of hepatitis C virus replications, were persistently
undetectable before and after 12 months of bosentan
treatment. At month 12, patient 2 remained free from
cirrhosis, based on ultrasonographic characteristics, and all
the 3 patients had no clinical evidence of HCC according to
serum AFP tests and hepatic ultrasonographic ﬁndings.
These ﬁndings suggested that long-term bosentan therapy
may offer a therapeutic option in patients with chronic HCV
infection; however, study of a larger cohort of patients is
warranted to conﬁrm the result.
Although the results of our study are promising, the
limitations are still obvious. Firstly, this single-centre
prospective study enrolled a small number of patients with
advanced IPAH. It needs to be emphasised that the total
number of IPAH patients who received regular bosentan
therapy in Taiwan was fewer than 50 until January 2006.
Additionally, this study excluded patients less than 12 years
of age because some of the paediatric patients could not
obey the orders required to complete the clinical examina-
tions. Secondly, the patients and investigators were not
blinded and there was also no control group due to ethical
considerations. Thirdly, we did not repeat right heart
catheterizations at 12 months of bosentan treatment
because we preferred to reserve this invasive follow-up
measurement for unclear situations, difﬁcult therapeutic
decisions or to use it prior to combination therapies when
IPAH was clinically worsening.Conclusion
This single-centre study of 12 Taiwanese patients with
advanced IPAH treated with long-term oral bosentan found
signiﬁcant improvements in NYHA FC, 6MWD, RVEF and
pulmonary function, as well as decreases in CTR compared
with baseline. Our observations suggest that long-term
bosentan therapy has favourable outcome and beneﬁcial
effects in Taiwanese IPAH patients, whether or not the
patients had chronic HCV infection.References
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